Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
DJ Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
1157 GMT - Roche's sales of Covid-19 tests will continue for longer than originally envisaged and will remain high into 3Q, as it is taking longer for the vaccination rollout to be completed, Credit Suisse says. The Swiss pharma major's share in PCR testing is strong and likely to be sustained for longer, it says. Furthermore, PCR tests will continue to be necessary even among vaccinated patients, who are likely to have much lower infection levels and so necessitate a more accurate test, the bank says, adding that Covid-19 is seen remaining a market opportunity for Roche in the low-single digit billion Swiss francs. Roche trades 0.8% lower at CHF306.80. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
March 24, 2021 07:57 ET (11:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
DJ罗氏从新冠肺炎获得的好处将在疫苗推出缓慢的情况下继续-市场对话
1157 GMT - Roche's sales of Covid-19 tests will continue for longer than originally envisaged and will remain high into 3Q, as it is taking longer for the vaccination rollout to be completed, Credit Suisse says. The Swiss pharma major's share in PCR testing is strong and likely to be sustained for longer, it says. Furthermore, PCR tests will continue to be necessary even among vaccinated patients, who are likely to have much lower infection levels and so necessitate a more accurate test, the bank says, adding that Covid-19 is seen remaining a market opportunity for Roche in the low-single digit billion Swiss francs. Roche trades 0.8% lower at CHF306.80. (cecilia.butini@wsj.com)
1157GMT-瑞士信贷称,罗氏新冠肺炎检测的销售将持续比最初预想的更长时间,并将保持高位进入第三季度,因疫苗推广完成所需的时间更长。该公司表示,这家瑞士制药巨头在PCR检测中的份额很大,可能会持续更长时间。此外,世行表示,即使是在接种疫苗的患者中,聚合酶链反应检测也将继续是必要的,这些患者的感染水平可能要低得多,因此需要进行更准确的检测。该行补充说,新冠肺炎被视为罗氏在低个位数10亿瑞士法郎的市场机会。罗氏股价下跌0.8%,至306.80瑞士法郎。(cecilia.butini@wsj.com)
(END) Dow Jones Newswires
(完)道琼通讯社
March 24, 2021 07:57 ET (11:57 GMT)
2021年3月24日东部时间07:57(格林尼治标准时间11:57)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧